DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in children with glioma (a type of brain tumour). This means they have gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Dabrafenib and trametinib work in patients with a particular mutation in their cancer known as BRAF V600. Investigators now wish to find out if they will be useful in treating patie

Trial Details

NCT ID
NCT07440290
Phase
PHASE2 / PHASE3
Sponsor
Cancer Research UK
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Dabrafenib
  • Trametinib
Locations (sample)
  • Belfast, United Kingdom|54.59682,-5.92541
  • Birmingham, United Kingdom|52.48142,-1.89983
  • Birmingham, United Kingdom|52.48142,-1.89983
  • Bristol, United Kingdom|51.45523,-2.59665
  • Bristol, United Kingdom|51.45523,-2.59665

Key Eligibility Criteria

  • Inclusion criteria:
  • A. Confirmed diagnosis of a malignancy harbouring an oncogenic alteration in BRAF V600, including Langerhans cell histiocytosis, using an analytica…
  • B. Patients ≥1 year old and ≥8 kg in body weight.
  • C. Women of childbearing potential are eligible provided that they meet the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →